Publicaciones en las que colabora con Pilar López Ruíz (29)

2014

  1. A tetradecapeptide somatostatin dicarba-analog: Synthesis, structural impact and biological activity

    Bioorganic and Medicinal Chemistry Letters, Vol. 24, Núm. 1, pp. 103-107

  2. Prostate anatomy in motheaten viable (mev) mice with mutations in the protein tyrosine phosphatase SHP-1

    Actas Urologicas Espanolas, Vol. 38, Núm. 7, pp. 438-444

2013

  1. Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells

    Cellular Signalling, Vol. 25, Núm. 7, pp. 1586-1597

  2. Insights into structure-activity relationships of somatostatin analogs containing mesitylalanine

    Molecules, Vol. 18, Núm. 12, pp. 14564-14584

2012

  1. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway

    Carcinogenesis, Vol. 33, Núm. 6, pp. 1169-1177

  2. Fine-tuning the π-π Aromatic interactions in peptides: Somatostatin analogues containing mesityl alanine

    Angewandte Chemie - International Edition, Vol. 51, Núm. 8, pp. 1820-1825

2011

  1. SHP-1 in cell-cycle regulation

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, Núm. 1, pp. 89-98

  2. SSTR1- and SSTR3-Selective Somatostatin Analogues

    ChemBioChem, Vol. 12, Núm. 4, pp. 625-632

2010

  1. Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery

    Oncogene, Vol. 29, Núm. 3, pp. 345-355

2007

  1. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: The modulator role of PI3K/Akt

    Neoplasia

2004

  1. Fosfotirosina fosfatasa SHP-1, somatostatina y cáncer de próstata

    Actas Urologicas Espanolas, Vol. 28, Núm. 4, pp. 269-285

2002

  1. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1

    Journal of Clinical Endocrinology and Metabolism, Vol. 87, Núm. 2, pp. 915-926

2000

  1. Modulation of guanosine triphosphatase activity of G proteins by arachidonic acid in rat Leydig cell membranes

    Endocrinology, Vol. 141, Núm. 3, pp. 1093-1099

1998

  1. Specific effect of arachidonic acid on 17β-hydroxysteroid dehydrogenase in rat Leydig cells

    FEBS Letters, Vol. 422, Núm. 1, pp. 10-14

1997

  1. Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate

    FEBS Letters, Vol. 406, Núm. 1-2, pp. 42-48

1996

  1. Different sites of action of arachidonic acid on steroidogenesis in rat Leydig cells

    Molecular and Cellular Endocrinology, Vol. 118, Núm. 1-2, pp. 193-200

1992

  1. Somatostatin inhibits VIP- and forskolin-stimulated cyclic AMP accumulation in enterocytes from rat jejunum.

    Epithelial cell biology, Vol. 1, Núm. 2, pp. 65-69

1990

  1. Somatostatin inhibition of VIP-and isoproterenol-stimulated cyclic AMP accumulation in dissociated cells from rat cerebral cortex

    Neuropeptides, Vol. 15, Núm. 4, pp. 235-239

1989

  1. Cysteamine normalizes cerebral somatostatin level and binding in pentylenetetrazol-kindled rats

    Life Sciences, Vol. 45, Núm. 25, pp. 2451-2458

  2. Long-term haloperidol treatment decreases somatostatin binding in rat brain

    Neuropeptides, Vol. 13, Núm. 3, pp. 157-163